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Context: The European Association of Urology Guideline Panel for Renal Cell Carcinoma
(RCC) has prepared evidence-based guidelines and recommendations for RCC manage-
ment.
Objectives: To provide an update of the 2010 RCC guideline based on a standardised
methodology that is robust, transparent, reproducible, and reliable.
Evidence acquisition: For the 2014 update, the panel prioritised the following topics:
percutaneous biopsy of renal masses, treatment of localised RCC (including surgical and
nonsurgical management), lymph node dissection, management of venous thrombus,
systemic therapy, and local treatment of metastases, for which evidence synthesis was
undertaken based on systematic reviews adhering to Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) guidelines. Relevant databases (Med-
line, Cochrane Library, trial registries, conference proceedings) were searched (January
2000 to November 2013) including randomised controlled trials (RCTs) and retrospec-
tive or controlled studies with a comparator arm. Risk of bias (RoB) assessment and
qualitative and quantitative synthesis of the evidence were performed. The remaining
sections of the document were updated following a structured literature assessment.
Evidence synthesis: All chapters of the RCC guideline were updated. For the various
systematic reviews, the search identiﬁed a total of 10 862 articles. A total of 151 studies
reporting on 78 792 patients were eligible for inclusion; where applicable, data from
RCTs were included and meta-analyses were performed. For RCTs, there was low RoB
across studies; however, clinical and methodological heterogeneity prevented data
pooling for most studies. The majority of studies included were retrospective with
matched or unmatched cohorts based on single or multi-institutional data or national
registries. The exception was for systemic treatment of metastatic RCC, in which several
RCTs have been performed, resulting in recommendations based on higher levels of
evidence.
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1. Introduction
The European Association of Urology (EAU) Renal Cell
Carcinoma (RCC) Guideline Panel has compiled these
clinical guidelines to provide clinicians with evidence-
based information and recommendations for the manage-
ment of patients with RCC. The RCC panel is an international
group consisting of clinicians with particular expertise in
this field. To meet the requirements for a multidisciplinary
approach, the panel has recently been reinforced by several
experts, including a medical oncologist, pathologists,
radiologists, amethodologist, biostatisticians, andmembers
of patient advocacy groups. The EAU RCC guidelines were
first published in 2000 [1], with a subsequent full update in
2006 and partial updates in 2007, 2008, 2009, 2010 [2], and
2013. The current 2014 document presents a full-text
update and is fundamentally different from the versions
published previously. The panel adopted Cochrane meth-
odology and Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines [3] in
undertaking systematic reviews (SRs) in 2011 to ensure
that the evidence synthesis was performed in a robust,
standardised, transparent, and reproducible manner. For
the 2014 update, the panel has proceeded with the SR work
in a stepwise fashion. The majority of sections have been
updated based on SRs; however, a few sections of the
document have been updated following a structured
literature assessment, as shown in Table 1. As a result,
the previous guideline has been completely revised and
supplemented with a section on management of venous
tumour thrombus. A detailed version of the current
guideline including full references, level of evidence, and
grade of recommendations is available at www.uroweb.org
[4]. The focus for the next 2 yr is for the complete guidelines
document to be based on SRs for evidence synthesis, as SRs
represent the highest possible level of data work-up.
2. Evidence acquisition
All chapters of the 2014 RCC Guidelines publication have
beenupdated.Asmentioned inTable 1, the consistencyof the
data work-up differed between sections. For the parts of
the guideline that have been updated by SR, the review
methodology is outlined in detail in several ensuing
publications [5,6]. In brief, SRs of the literature were
conducted in accordancewith PRISMA guidelines [3]. Impor-
tant topics andquestionswereprioritisedby thepanel for the
present update. For each SR, elements for inclusion and
exclusion, including patient population, intervention, com-
parison, outcomes (PICO), study design, and search terms
and restrictions, were developed using an iterative process
involving all members of the panel to achieve consensus.
Where relevant, confounding variables were identified for
each question to facilitate the assessment of nonrandomised
studies. Individual literature searches were conducted
separately for each update question using the following
databases: Medline, Medline In-Process, Embase, Cochrane
Controlled Trials Register (The Cochrane Library, Issue 10,
October 2013), and the Latin American and Caribbean Center
onHealth Sciences Information (LILACS). In addition, SRs and
other background information were identified by searching
the Cochrane Database of Systematic Reviews (The Cochrane
Library, Issue 10, October 2013). The SR protocols containing
details of the review process and search strategies used have
been published on www.uroweb.org [7]. In addition, the
reference lists of all the studies included were scanned to
identify additional potentially relevant studies, and reports
identified by the panel served as an additional source for
Conclusions: The 2014 guideline has been updated by a multidisciplinary panel using
the highest methodological standards, and provides the best and most reliable
contemporary evidence base for RCC management.
Patient summary: The European Association of Urology Guideline Panel for Renal Cell
Carcinoma has thoroughly evaluated available research data on kidney cancer to
establish international standards for the care of kidney cancer patients.
# 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Table 1 – Description of the update and summary of the review methodology for 2014
Chapter Description of review methodology
1. Introduction Not applicable
2. Epidemiology and aetiology Updated using a structured data assessment
3. Diagnosis and staging Updated using a systematic review on tumour biopsy and a traditional narrative review for
the other aspects of diagnosis and staging
4. Classiﬁcation and prognostic factors Updated using a structured data assessment
5. Other renal tumours Updated using a traditional narrative review, based on a structured literature search; of
particular note is the inclusion of the new Vancouver Classiﬁcation in the Histology section
6. Treatment of localised disease Updated using systematic reviews for management of small renal masses, lymph node
dissection, and local treatment of metastases
A new section, Management of RCC with venous thrombus, has been added that is based on
a systematic review
7. Systemic therapy for metastatic disease Updated using a systematic review
8. Surveillance following radical or partial
nephrectomy or ablative therapies
Updated based on a traditional narrative review, based on a structured data search
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studies. Inmost instances the searchwas conductedup to the
endofNovember2013. Two independent reviewers screened
abstracts and full texts, carried out data abstraction, and
assessed the risk of bias (RoB). The results were presented in
tables showing baseline characteristics and summaries of
findings.Meta-analyseswereperformedonly for randomised
controlled trials (RCTs) if consistency and homogeneity of
data were demonstrated. When this was not possible,
a narrative synthesis of the evidence was provided. The
remaining parts of the guideline have been updated using a
traditional narrative review strategy.
References were assessed according to their level of
scientific evidence (LE), and guideline recommendations
were graded according to the 2009 Oxford Centre for
Evidence-based Medicine Levels of Evidence (http://www.
cebm.net/index.aspx?o=1025).
3. Evidence synthesis
Themajority of the studies included in this guideline update
are retrospective analyses that include some larger multi-
centre studies andwell-designed controlled studies. As only
a few RCTs are available, most of the data are not based on
high levels of evidence. The exception was for systemic
treatment of metastatic RCC (mRCC), for which several RCTs
have been performed, resulting in recommendations based
on higher levels of evidence.
3.1. Epidemiology and aetiology
RCC represents 2–3% of all cancers, with the highest
incidence occurring inWestern countries. In general, during
the last two decades there has been an annual increase of
approximately 2% in incidence both worldwide and in
Europe until recently, with approximately 84 400 new RCC
cases and 34 700 kidney cancer-related deaths within the
European Union in 2012 [8]. In Europe, overall mortality
rates for RCC increased up until the early 1990s, with rates
generally stabilising or declining thereafter [9]. There
has been a decrease in mortality since the 1980s in
Scandinavian countries and since the early 1990s in France,
Germany, Austria, the Netherlands, and Italy. However, in
some European countries (Croatia, Estonia, Greece, Ireland,
Slovakia), mortality rates still show an upward trend. with
increasing rates [9]. RCC is the most common solid lesion
within the kidney and accounts for approximately 90% of all
kidney malignancies. It comprises different RCC subtypes
with specific histopathological and genetic characteristics
[10]. There is a 1.5:1 predominance in men over women,
with peak incidence occurring between 60 and 70 yr of
age. Aetiological factors include lifestyle variables such
as smoking, obesity, and hypertension [11]. Having a first-
degree relativewith kidney cancer is also associatedwith an
increased risk of RCC. A number of other factors have been
suggested as being associated with higher or lower risk of
RCC, but have not been confirmed. These include specific
dietary habits and occupational exposure to specific
carcinogens, but the literature is inconclusive [12]. Moder-
ate alcohol consumption appears to have a protective effect
for reasons not yet known [13]. The most effective
prophylaxis is to avoid cigarette smoking and reduce
obesity. Currently, more than 50% of RCCs are detected
incidentally when abdominal ultrasound (US) or computed
tomography (CT) is carried out for other medical reasons
(LE 3). This has led to an increase in the incidence of small
renal masses (RMs), defined as contrast-enhancing masses
with a greatest dimension of 4 cm or less on abdominal
imaging [14].
3.2. Diagnosis and staging
3.2.1. Symptoms
Many patients with RMs remain asymptomatic until the
late stages of the disease. It has been reported that the
prevalence of the classic triad of flank pain, gross
haematuria, and a palpable abdominal mass in some parts
of theworld is lower than previously observed (now 6–10%)
and correlates with advanced disease and subtypes
associated with poor prognosis (LE 3) [15]. Paraneoplastic
syndromes are found in approximately 30% of patients with
symptomatic RCCs (LE 4). A few patients present with
symptoms caused by mRCC, such as bone pain, deteriora-
tion of performance status (PS), or persistent cough (LE 3)
[16].
3.2.2. Imaging
The traditional approaches for detecting and characterising
RMs are US, CT, and magnetic resonance imaging (MRI;
Table 2). RMs can be classified as solid or cystic on the basis
of the imaging findings. For solid RMs, the most important
criterion for differentiating malignant lesions is the
presence of contrast enhancement or restriction on MRI
(LE 3) [17]. Most RMs can be diagnosed accurately using
imaging alone. Contrast-enhanced US can be helpful in
specific cases (eg, chronic renal failure with a relative
contraindication for iodinated or gadolinium contrast
media, complex cystic masses, and differential diagnosis
of peripheral vascular disorders such as infarction and
cortical necrosis) (LE 3) [18]. However, CT and MRI features
cannot reliably distinguish oncocytoma and fat-free angio-
myolipoma from malignant renal neoplasms (LE 3)
[19,20]. Advanced MRI techniques such as diffusion-
weighted and perfusion-weighted imaging are being
explored in RM assessment [21]. Positron emission
tomography (PET) is not currently a standard investigation
(LE 3) [22]. In patients with RCC, chest CT is the most
accurate investigation to diagnose lung metastases or
enlarged mediastinal lymph nodes (LE 3) [23]. Since most
bone and brain metastases mostly are symptomatic at
diagnosis routine bone or brain imaging is only performed
on indication (LE 3) [24]. In the case of a renal cystic mass,
the Bosniak classification distinguishes five categories
according to CT presentation. Bosniak classification can
predict the risk of malignancy (LE 3) and provide guidance
for management [25]. Bosniak 1, 2, 2F, 3, and 4 cysts
are malignant in 0%, 0%, 25%, 54%, and 100% of cases,
respectively [26].
E U RO P E AN URO L OGY 6 7 ( 2 0 1 5 ) 9 1 3 – 9 2 4 915
3.2.3. Renal biopsy
Percutaneous renal tumour biopsies are increasingly being
used (1) for histological diagnosis of radiologically indeter-
minate RMs to avoid surgery in the event of benign lesions;
(2) to select patients with small RMs for surveillance
approaches; (3) to obtain histology before ablative treat-
ments; and (4) to select the most suitable medical and
surgical treatment strategy in the setting of mRCC (LE 3)
[27–29]. Needle core biopsies are preferable for solid RMs in
comparison with fine needle aspiration (LE 2b). Core
biopsies should be performed with 18G needles and a
coaxial technique to minimise the risk of complications
and seeding (LE 2b) [28,30,31]. Either a US- or CT-guided
approach can be used according to tumour and patient
characteristics (LE 2b) [28,30]. At least two quality cores
(nonfragmented, >10 mm in length) should be obtained,
and necrotic areas should be avoided to maximise
diagnostic accuracy (LE 4) [30,32]. Peripheral biopsies are
preferable for larger tumours to avoid the central necrosis
(LE 2b) [33]. Core biopsies of solid RMs have shown a
diagnostic yield of 78–97%, with high specificity (98–100%)
and high sensitivity (86–100%) for the diagnosis of
malignancy (LE 2b) [34]. However, it has been reported
that core biopsies are nondiagnostic in 2.5–22.0% of cases
(LE 2b) [34]. If a biopsy is nondiagnostic but there are
radiological findings suspicious for malignancy, a further
biopsy or surgical exploration should always be considered
(LE 4). Owing to the high diagnostic accuracy of current
imaging, a biopsy is not necessary in the setting of localised
or locally advanced disease before surgical treatment in fit
patients with a long life expectancy and a highly suspicious,
contrast-enhancing RM on CT or MRI (LE 4). Core biopsies
should not be recommended for cystic RMs, unless areas
with a solid pattern are present (Bosniak 4 cysts; LE 2b)
[28,30].
3.2.4. Histological diagnosis
Renal neoplasms comprise a broad spectrum of histopath-
ological entities described in the 2004 WHO classification
and modified by the International Society of Urological
Pathology (ISUP) Vancouver Classification (Section 3.4)
[35]. From a clinical viewpoint, threemain RCC subtypes are
important: clear cell RCC (ccRCC; 80–90%), papillary RCC
(pRCC types I and II; 10–15%, of which 60–70% are type I),
and chromophobe RCC (chRCC; 4–5%). There are differences
in tumour stage, grade, and cancer-specific survival (CSS)
between RCC subtypes, and they have an impact on
prognosis (Section 3.3). The 5-yr overall survival (OS) for
all RCC subtypes is 49%, which has further improved since
2006, probably because of an increase in incidentally
detected RCCs and the introduction of targeted therapies
[36]. Sarcomatoid differentiation can be found in all RCC
subtypes and is equivalent to high-grade and very aggres-
sive tumours (Section 3.4). Collecting duct carcinoma and
other infrequent renal tumours are discussed in Section 3.4
(Table 3).
3.3. Classification and prognostic factors
3.3.1. TNM stage classification
The latest version of the TNMclassificationwas published in
2010 and should be used for clinical and scientific staging
purposes. The prognostic value of the 2010 TNM classifica-
tion has been validated in both single- and multi-
institutional studies [37]. However, the subclassification
of T1 tumours using a cutoff of 4 cm might not be optimal
with the widening indication for nephron-sparing surgery
for localised RCC. In addition, the value of size stratification
of T2 tumours has been questioned [38]. In comparison to
the 2009 version, there is no longer any distinction between
N1 metastasis in a single regional lymph node and N2
metastases in more than one regional lymph node. Instead,
N1 comprises metastasis in regional lymph node(s) [37].
3.3.2. Prognostic factors
Prognosis is influenced by anatomical, histological, clinical,
and molecular factors. Anatomical factors are reflected in
the TNM classification and provide the most reliable
prognostic information. In addition, objective anatomical
classification systems such as the Preoperative Aspects and
Dimensions Used for an Anatomical (PADUA) classification
system, the RENAL nephrometry score, and the C-index
have been proposed to standardise the description of renal
tumours and aid in comparing nephron-sparing treatment
strategies [39–41]. Histological factors include nuclear
grade, RCC subtype, sarcomatoid features, microvascular
Table 2 – Key recommendations on diagnosis, staging, classification, and prognosis in patients with renal tumours
Recommendation GR
Contrast-enhanced multiphase abdominal CT and MRI are recommended for work-up of patients with RCC and are considered
equal for both staging and diagnosis
B
Contrast-enhanced multiphase abdominal CT and MRI are the most appropriate imaging modalities for renal tumour characterisation
and staging before surgery
C
A chest CT is recommended for staging assessment of the lungs and mediastinum C
A bone scan is not routinely recommended C
A renal tumour biopsy is recommended before ablative therapy and systemic therapy without previous pathology C
A percutaneous biopsy is recommended in patients in whom active surveillance is pursued C
A percutaneous renal tumour biopsy should be obtained with a coaxial technique C
Use of the current TNM classiﬁcation system is recommended. B
Grading systems and classiﬁcation of RCC subtype should be used B
Prognostic risk models should be used in the metastatic setting B
CT = computed tomography; GR = grade of recommendation; MRI = magnetic resonance imaging: RCC = renal cell carcinoma.
E U RO P E AN URO LOG Y 6 7 ( 2 0 1 5 ) 9 1 3 – 9 2 4916
invasion, tumour necrosis, and invasion of the collecting
system. Although affected by intra- and interobserver
discrepancies, grade remains an independent prognostic
factor [42]. At the ISUP conference, a simplified nuclear
grading system, based only on the size and shape of
nucleoli, was proposed to replace the Fuhrman grading
system [35]. Regarding RCC subtypes, there is a trend in
univariate analysis towards better prognosis for patients
with chRCC versus pRCC (with pRCC type II worse than
ccRCC) versus ccRCC [43]. However, the prognostic infor-
mation provided by RCC subtype is lost when stratified to
tumour stage (LE 3) [43]. For localised RCC, several risk
scores and nomograms can be used, including the Stage,
Size, Grade, and Necrosis Score (SSIGN) [44], a modified
version of the SSIGN score (Leibovich score) [45], the
University of California Los Angeles Integrated Staging
System (UISS) [46], and Karakiewicz’s nomogram (LE 3)
[47]; Section 3.7 provides further details. Clinical factors
include patient PS, localised symptoms, cachexia, anaemia,
elevated neutrophil and platelet counts, and other labora-
tory parameters, and are predominantly used in prognostic
risk models in mRCC (LE 3) [48,49]. Numerous molecular
markers including gene expression profiling and deep and
whole-genome–wide sequencing have been investigated,
but none of these techniques has yet yielded markers or
profiles that improve the predictive accuracy of current
prognostic systems. Their use is therefore not recom-
mended in routine practice. There is hope that molecular
techniques will augment the current pre- and postoperative
prognostic nomograms and the risk scores for mRCC, which
have C-indices of 0.63–0.84 and have reached a plateau in
accuracy based on histological and clinical factors [49].
3.4. Other renal tumours
A revised histopathological classification was published in
2013 as the ISUP Vancouver classification of renal neoplasia
[35]. This classification will probably constitute the basis
of the new WHO classification to replace the 2004 version.
The common RCC subtypes (Section 3.2.4.) account for
85–90% of renal malignancies. The remaining 10–15% of
renal tumours include renal pelvis carcinoma and a variety
of uncommon, sporadic, and familial carcinomas, some
of which have recently been described, and a group of
unclassified carcinomas. For these generally rare renal
tumours, Table 3 summarises their malignant potential
and universal grade C recommendations for treatment,
if localised. Extensive details are provided in the full
guidelines [4].
3.5. Treatment of localised RCC and local treatment of mRCC
Six SRs underpin the recommendations of this section
(Supplementary Table 1) [7]. These reviews included all
relevant published literature comparing surgical manage-
ment of localised RCC (T1–2N0M0) [50,51], different strate-
gies for small RMs, lymphadenectomy and adrenalectomy
[6], caval venous thrombus, and local therapy of metastases
from RCC. Owing to the very limited number of RCTs,
nonrandomised studies (NRSs), prospective observational
studies with controls, retrospective matched-pair studies,
and comparative studies from the databases of well-defined
registries were also included. Studies with no comparator
group (eg, case series), unmatched retrospective studies, and
chart reviews were excluded because of their inherent RoB.
3.5.1. Surgical treatment
For localised RCC, surgery is the only curative treatment
with high-quality evidence. According to oncological and
quality-of-life outcomes, localised T1a–b tumours are best
managed by partial nephrectomy (PN) rather than radical
nephrectomy (RN), if technically feasible, irrespective of the
surgical approach (LE 1b; Table 4). A prospective RCT
compared RN with PN in solitary T1a–b N0M0 renal
tumours <5 cm with normal contralateral kidney function
and WHO PS 0–2. At 9.3-yr follow-up, 198 patients (72.5%)
were alive after RN and 173 (64.4%) after PN, with CSS of
98.5% and 97%, respectively. Local recurrence occurred in
Table 3 – Summary of other renal tumours with an indication of malignant potential and recommendation for treatment (all grade C)
Entity Malignant potential Treatment of localised tumour
Sarcomatoid variants of RCC High Surgery
Multilocular clear cell RCC Low, no metastasis Surgery, NSS
Carcinoma of the collecting ducts of Bellini High, very aggressive Surgery, discussable for M+ tumours
Renal medullary carcinoma High, very aggressive Surgery
Translocation RCC Xp11.2 High Surgery
Translocation RCC t(6;11) Low Surgery, NSS
Tubulocystic RCC Low Surgery, NSS
Mucinous tubular and spindle cell carcinoma Intermediate Surgery, NSS
Acquired cystic disease-associated RCC Low Surgery
Clear cell (tubulo) papillary RCC Low Surgery, NSS
Hybrid oncocytic chromophobe tumour Low Surgery, NSS
Metanephric tumours Benign Surgery, NSS
Cystic nephroma/mixed epithelial and stromal tumour Low/benign Surgery, NSS
Oncocytoma Benign Observation (when histologically conﬁrmed)/surgery, NSS
Hereditary kidney tumours High Surgery, NSS
Angiomyolipoma Benign Consider treatment only in very well-selected patients
Unclassiﬁed RCC Variable Surgery, NSS
NSS = nephron-sparing surgery; RCC = renal cell carcinoma.
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one patient in the RNgroup and six patients in the PN group
[52]. Many retrospective studies compared PN to RN (open
or laparoscopic) for RCC<4 cm [4,50,53] anddemonstrated
an association between RN and increased cardiovascular
events and mortality from any cause after adjusting for
patient characteristics. In studies analysing RCCs of
4–7 cm, no CSS differences were observed between PN
and RN [50]. No prospective comparative studies were
identified reporting ononcological outcomes forminimally
invasive ablative procedures compared with RN. One trial
reported on radiofrequency ablation (RFA) versus RN or PN
for T1a RCC; CSS of 100% was observed for each of the
three treatment modalities [50]. If PN is not feasible, the
curative therapy remains RN, which includes removal of
the tumour-bearing kidney. Complete resection of the
primary tumour with PN or RN performed via either open
or laparoscopic surgery offers a reasonable chance of cure.
Ipsilateral adrenalectomyduringRNor PNdoes not provide
a survival advantage (LE 3). In patients with localised
disease and no clinical evidence of lymph nodemetastases,
there is no proof of any survival advantage of lymph node
dissection (LE 1b). In patients with localised disease and
clinically enlarged lymph nodes, the survival benefit of
lymph node dissection is not demonstrated. However, such
dissection can be performed for staging purposes (LE 3).
3.5.2. RN techniques
There are no RCTs assessing oncological outcomes of
laparoscopic RN versus open RN. A prospective cohort
study and several retrospective database reviews are
available, mostly of low methodological quality. These
studies showed similar oncological outcomes for laparo-
scopic versus open RN, but a significantly shorter hospital
stay and lower analgesic requirement for the laparoscopic
compared with the open group [50,51]. On the basis
of these data, laparoscopic RN has lower morbidity
compared to open surgery (LE 1b). Similar oncological
outcomes were reported for both retroperitoneal
and transperitoneal approaches in two RCTs and one
quasi-randomised study [54]. No reliable comparative
data exist with regard to hand-assisted, robotic, and
laparoendoscopic single-site nephrectomy versus the
conventional laparoscopic approach.
3.5.3. PN techniques
Studies comparing laparoscopic PN and open PN found
no difference in progression-free survival (PFS) or OS
between the techniques in centres with laparoscopic
expertise [55–57]. The mean estimated blood loss was
generally lower with the laparoscopic approach, but warm
ischaemia time (WIT) was prolonged [56]. In a matched-
pair comparison, the decline in glomerular filtration rate
was greater in the laparoscopic PN group in the immediate
postoperative period [55], but not after a follow-up of
3.6 yr. Retroperitoneal and transperitoneal laparoscopic PN
yielded similar perioperative outcomes. In a large, retro-
spective, multicentre comparative study, simple tumour
enucleation had similar PFS and CSS rates to standard PN
and RN [58]. At present, no study has compared the
oncological outcomes of robot-assisted versus laparoscopic
PN. A prospective comparison of surgical outcomes
obtained after robotic or pure laparoscopic PN in moderate
to complex renal tumours showed significantly lower
estimated blood loss and shorter WIT in the robotic group
[59]. Meta-analyses of relatively small series found
comparable perioperative outcomes and shorter WIT for
robot-assisted PN [60]. In conclusion, PN can be performed,
either with an open, pure laparoscopic, or robot-assisted
approach, according to the surgeon’s expertise and skills
and equipment availability (LE 2b).
3.5.4. Management of RCC with venous thrombus
An RCC tumour thrombus in the inferior vena cava (IVC)
is a significant adverse prognostic factor (Section 3.3.1.).
Traditionally, patients with venous tumour thrombus (VTT)
usually undergo RN and thrombectomy. Aggressive surgical
resection is widely accepted as the default management
for VTT [61]. However, uncertainties remain regarding
the surgical treatment, especially in terms of comparative
effectiveness and harms. There is variation in how the
surgery is undertaken in terms of preoperative strategies
(eg, use of IVC filter or preoperative embolisation), the
surgical approach for IVC access, and bypass procedures
to achieve vascular control (eg, venovenous bypass or
cardiopulmonary bypass and deep hypothermic circulatory
arrest). To determine the evidence base for these different
strategies, an SR of the literature was undertaken, including
Table 4 – Key recommendations for treatment of localised RCC and local treatment of metastatic RCC
Recommendation GR
Nephron-sparing surgery is recommended in patients with T1a tumours A
Nephron-sparing surgery should be favoured over radical nephrectomy in patients with T1b tumours when technically feasible B
Ipsilateral adrenalectomy is not recommended when there is no clinical evidence of invasion of the adrenal gland B
Lymph node dissection is not recommended for localised tumours without clinical evidence of lymph node invasion A
In patients with clinically enlarged lymph nodes, lymph node dissection can be performed for staging purposes or local control C
Laparoscopic radical nephrectomy is recommended for patients with T2 tumours and localised renal masses not treatable by
nephron-sparing surgery
B
Owing to the low quality of the available data, no recommendation can be made on radiofrequency ablation or cryoablation C
In the elderly and/or comorbid patients with small renal masses and limited life expectancy, active surveillance, radiofrequency
ablation, and cryoablation can be offered
C
Cytoreductive nephrectomy is recommended in appropriately selected patients with metastatic RCC C
Bosniak cysts greater than type III should be regarded as RCC and be treated accordingly C
GR = grade of recommendation; RCC = renal cell carcinoma.
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comparative studies only reporting on management of VTT
in non-mRCC (nmRCC; Supplementary Table 1) [7]. Only
five retrospective studies [4] were eligible for inclusion, all
with significant RoB, none of which addressed the question
of whether patients with nmRCC and VTT derive a benefit
from surgery to remove the thrombus, and how throm-
bectomy influences prognosis from an oncological perspec-
tive. Nevertheless, the findings support the notion that all
patients with nmRCC and VTT should be considered for
surgical intervention, irrespective of the extent of tumour
thrombus at presentation (LE 3). PS can significantly
improve after removal; therefore, deterioration of PS due
to thrombus should not be an exclusion criterion for
surgery, There is no distinct surgical method that seems
superior for VTT excision, although the surgical method
appears to depend on the VTT level and the grade of
occlusion of the IVC. For adequate removal of the thrombus,
caval vein control is key, which may require liver
mobilisation and cardiac bypass. Preoperative embolisation
does not seem to have any clinical value. The relative
benefits and harms of other strategies and approaches
regarding IVC access and the role of IVC filters and bypass
procedures remain uncertain.
3.5.5. Therapeutic approaches as alternatives to surgery
3.5.5.1. Embolisation. Before a routine nephrectomy, there
is no benefit in performing tumour embolisation [62].
In patients unfit for surgery and suffering from massive
haematuria or flank pain, embolisation can be a beneficial
palliative intervention (LE 3).
3.5.5.2. Surveillance. Elderly and comorbid patients with
incidentally detected small RMs have relatively low RCC-
specific mortality and significant competing-cause mortal-
ity [63]. Active surveillance can be offered to this category of
patients and is defined as initial monitoring of tumour size
via serial abdominal imaging (US, CT, or MRI), with delayed
intervention reserved for tumours that show clinical
progression during follow-up. As mentioned, a renal biopsy
is recommended before inclusion of patients in surveillance
approaches (LE 3). In the largest reported active surveillance
series, RM growth was low (average 0.13 cm/yr) in most
cases and progression to mRCC was rare (1–2%; LE 3)
[63]. The frequency of serial imaging in this study consisted
of CT, MRI, or US at 3 and 6 mo, then every 6 mo until 3 yr,
and then annually (LE 3).
3.5.5.3. Ablative therapies. The most commonly performed
minimally invasive approaches besides surgery include
percutaneous RFA, laparoscopically assisted or percutaneous
cryoablation (CA), microwave ablation, stereotactic radio-
surgery, laser ablation, and high-intensity focused US
ablation.With the exception of RFA andCA,most approaches
are experimental. Indications for thermal ablation include
small RMs in elderly comorbid patients considered unfit
for surgery, those with a genetic predisposition to develop
multiple tumours, and patients with bilateral tumours or
with a solitary kidneyandahigh risk of complete loss of renal
function following PN. Larger tumours or those located at the
hilum or near the proximal ureter are not recommended for
ablation. There are no RCTs comparing RFA or CA with PN.
Low-quality studies suggest a higher local recurrence rate for
thermal ablation comparedwith PN (LE 3). The quality of the
available data does not allow any definitive conclusions
regarding morbidity and oncological outcomes for RFA and
CA (LE3) [64].
3.5.6. Adjuvant therapy
Several phase 3 RCTs of adjuvant sunitinib, sorafenib,
pazopanib, axitinib, and everolimus are ongoing. Until
results from these studies are reported, there is no evidence
to support the use of adjuvant therapy after RCC surgery.
Prior RCTs with cytokines, chemotherapy, or vaccines were
largely negative [65].
3.5.7. Surgical treatment of mRCC (cytoreductive nephrectomy)
RCC surgery is curative only if all the tumour burden can
be removed. Retrospective data suggest that this goal
is achievable in patients with single- or oligometastatic
disease that is amenable to surgery. For most patients with
mRCC, cytoreductive nephrectomy (CN) is palliative and
systemic treatment is necessary. In a meta-analysis of two
RCTs comparing CN plus immunotherapy versus immuno-
therapy alone, there was a significant increase in long-term
survival in patients treated with CN [66]. At present, only
retrospective data are available for comparison of CN
combined with targeted agents to systemic therapy alone;
these data suggest that patients with good PS or risk scores
may benefit from surgery [67]. Results for the randomised
phase 3 CARMENA and EORTC SURTIME studies are
awaited. CN is currently recommended in mRCC patients
with good PS, large primary tumours, and low metastatic
volume. In patients with poor PS or International mRCC
Database Consortium (IMDC) risk, those with small
primaries and highmetastatic volume and/or a sarcomatoid
tumour, CN is not recommended.
3.5.8. Local therapy of metastases in RCC
An SR was undertaken of all types of comparative study
on local treatment of metastases from RCC in any organ
(Supplementary Table 1) [68]. Relevant interventions
included metastasectomy, various radiotherapy modalities,
and no local treatment [7]. The outcomes were survival (OS,
CSS, and PFS), local symptom control, and adverse events.
All studies included were retrospective, nonrandomised,
comparative studies, resulting in high RoB associated
with nonrandomisation, attrition, and selective reporting
[68]. With the exception of brain and possibly bone
metastases frequently treated by stereotactic radiotherapy,
metastasectomy remains by default an appropriate local
treatment for most sites. Retrospective comparative
studies consistently point towards a benefit of complete
metastasectomy in mRCC patients in terms of OS, CSS,
and delay of systemic therapy. Radiotherapy, especially
stereotactic radiotherapy, for bone and brain metastases
from RCC can induce significant relief from local symptoms
(all LE 3).
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3.6. Systemic therapy for mRCC
An SR was undertaken to analyse evidence for first and
subsequent lines of treatment, combinations, and RCC
subtypes (Supplementary Table 1) [5,7].
3.6.1. Clear-cell mRCC
In patients with clear-cell (cc)-mRCC, chemotherapy is not
effective. Recent advances inmolecular biology have led to
the development of several novel agents for treating mRCC
(Table 5). As a consequence, monotherapy with interferon
(IFN)-a or high-dose bolus interleukin (IL)-2 should no
longer be routinely recommended as first-line therapy
in mRCC, except in certain circumstances (eg, lung
metastasis, cc-mRCC, long interval). In sporadic cc-mRCC,
hypoxia-inducible factor (HIF) accumulation due to von
Hippel-Lindau (VHL) inactivation results in overexpression
of vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF), both of which promote
neoangiogenesis [69]. This process substantially contrib-
utes to thedevelopment andprogressionof RCC. At present,
there are seven targeted drugs approved in the USA
and Europe for treating mRCC: sorafenib; sunitinib;
bevacizumab combined with IFN-a; pazopanib; temsir-
olimus; everolimus; and axitinib. A detailed review of the
registration trials is available in the online guideline
[4]. Since the Memorial Sloan-Kettering Cancer Center
(MSKCC) (Motzer) criteria were developed during the
cytokine era [70], the IMDC has established and validated a
risk model for patients treated in the era of targeted
therapy that should be preferred. Neutrophilia and
thrombocytosis have been added to the list of MSKCC risk
factors, while lactate dehydrogenase (LDH) has been
removed [49]. To accurately select treatment for patients,
risk stratification according to prognostic scores should be
performed and the subtype should be established (LE 1b
based on results of RCTs using risk stratification [5,71,72]).
Pivotal phase 3 trials have established sunitinib and
bevacizumab plus IFN-a as first-line treatment options
in treatment-naı¨ve patients with cc-mRCC and good to
intermediate risk [71,72]. The COMPARZ study, which had
a noninferiority design, demonstrated that pazopanib and
sunitinib have similar efficacy but different toxicity
profiles [73]. The study therefore firmly established
pazopanib as another first-line option. On the basis of trial
results and limitations in study design, axitinib is not
approved for therapy of treatment-naı¨ve mRCC. For
patients with (modified) poor-risk mRCC, an RCT demon-
strated longer PFS and OS for temsirolimus compared to
IFN-a alone or combined with temsirolimus (LE 1b)
[74]. Despite several attempts, combination therapy using
currently approved targeted drugs did not demonstrate a
benefit in comparison to single-agent use, mainly because
of tolerability issues. Therefore, there is a need to sequence
available agents according to RCT results [5]. Several
phase 2 and 3 trials have investigated therapeutic options
for patients who have progressed on cytokines and first-
line VEGF-targeted therapy. Axitinib and everolimus both
met their primary endpoints in randomised phase 3 trials
(AXIS and RECORD-1) in the VEFG-resistant setting, and
sorafenib is a reasonable treatment option. No firm
recommendations can currently be made regarding the
best sequence for targeted therapy [5]. The therapeutic
recommendations and evidence base are summarised in
Table 5. For a list of graded key recommendations, see
Supplementary Table 2.
Table 5 – European Association of Urology 2014 evidence-based recommendations for systemic therapy in patients with mRCC
RCC type MSKCC
risk group [70]
First line LE e Second line a LE e Third line a LE e Later lines LE



































Clear cell a Poor c Temsirolimus 1b Any targeted agent






Any targeted agent 4
IFN = interferon; LE = level of evidence; MSKCC =Memorial Sloan-Kettering Cancer Center; mTOR = mammalian target of rapamycin inhibitor; mRCC = metastatic
renal cell carcinoma; RCC = renal cell carcinoma; TKI = tyrosine kinase inhibitor; VEGFR = vascular endothelial growth factor receptor.
a Doses: IFN-a9MU three times per week subcutaneously; bevacizumab 10mg/kg biweekly intravenously; sunitinib 50mg daily orally for a period of 4 wk, followed
by 2 wk of rest (37.5 mg continuous dosing did not show signiﬁcant differences); temsirolimus 25mgweekly intravenously; pazopanib 800 mg daily orally; axitinib
5 mg twice daily, to be increased to 7 mg twice daily, unless greater than grade 2 toxicity, blood pressure >150/90 mm Hg, or the patient is taking antihypertensive
medication; everolimus 10mg daily orally.
b No standard treatment available. Patients should be treated in the framework of clinical trials. If a trial is not available, a decision can be made in consultation with
the patient to perform treatment in line with clear-cell renal cell carcinoma.
c Poor risk criteria in the NCT00065468 trial consisted of MSKCC [70] risk plus metastases in multiple organs.
d Sorafenib was inferior to axitinib in a RCT in terms of PFS but not OS (34).
e Level of evidence was downgraded in instances when data was obtained from subgroup analysis within an RCT.
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3.6.2. Non–clear-cell mRCC
No phase 3 trials on systemic treatment of patients with
non–clear-cell (ncc)-mRCC have been reported. Expanded
access programs and subset analysis from RCC studies
suggest that the outcome of targeted therapy in these
patients is inferior to that for cc-mRCC. Targeted treatment
in ncc-mRCC has focused on temsirolimus, everolimus,
sorafenib, and sunitinib, and data have been reported from
single-arm phase 2 trials [5]. A randomised phase 2 trial of
everolimus versus sunitinib with crossover design in ncc-
mRCC included 73 patients (27with pRCC) andwas stopped
after a futility analysis for PFS and OS. Median OS for
everolimus was 10.5 mo but was not reached for sunitinib
[75]. The final results presented at the 2014 annual meeting
of the American Society of Clinical Oncology showed a
nonsignificant trend favouring sunitinib. Both sunitinib and
everolimus remain options in this population, with a
preference for sunitinib. Patients with ncc-mRCC should
be referred to a clinical trial where appropriate.
3.7. Surveillance following nephrectomy or ablative therapies
Surveillance after treatment for RCC allows the clinician to
monitor or identify postoperative complications, renal
function, local recurrence after PN or ablation, recurrence
in the contralateral kidney, and development of metastases.
Since the last guideline update was published in 2010, the
evidence base for follow-up strategies has not changed
[2]. There is a clear need for further research to determine
whether follow-up benefits patient survival, to identify the
time point at which restaging has the best chance of
detecting recurrence, and to develop prognostic markers at
surgery for the risk of relapse over time. The current
conclusions are that the aim of surveillance is to detect
either de novo lesions in the kidney or local recurrence or
metastases while the patient is still surgically curable.
In addition, renal function should be assessed. To tailor
follow-up and avoid unnecessary intensive surveillance
with imaging, risk stratification should be based on risk
assessment scores. Despite validation, none of the proposed
models or nomograms is 100% accurate, with C-indices
ranging from 74% to 82.2% for assessment of recurrence and
from 68% to 89% for assessment of cancer-specific mortality
[76]. A commonly usedmodel is the UISS integrated staging
system using TNM stage, Eastern Cooperative Oncology
Group PS, and nuclear grade [46,77]. The SSIGN score adds
necrosis and tumour size and has been modified by
Leibovich [44,45]. Overall, because of a lack of 100%
accuracy, historical differences in the use of TNM staging
systems, and differences in assessments (OS, CSS, mortality,
recurrence-free survival) and subtypes (ccRCC only vs all
subtypes), no preference for a risk stratification model can
be given. A plateau has been reached in accuracy and a
certain error rate has to be accepted for all models.
However, the risk groups established for low, intermediate,
and high risk allow tailoring of follow-up protocols, and one
of the models should be chosen for use in routine clinical
practice. The following recommendations can be made
based on LE 4: (1) for low-risk disease, cross-sectional
imaging (CSI) with CT/MRI can be used infrequently; (2) in
the intermediate-risk group, intensified follow-up should
be performed, including CSI at regular intervals; and
(3) in high-risk patients, follow-up examinations should
include routine CSI in the first few years following
treatment. There is an increased risk of intrarenal recur-
rence in larger (>7 cm) tumours treated with PN, or when
there is a positive margin. Follow-up should be intensified
in such patients. Table 6 proposes a risk-adapted follow-up
algorithm.
4. Conclusions
These updated 2014 guidelines provide the current
evidence base for the management of RCC according to
the most robust and reliable standards. In contrast to
previous versions, a multidisciplinary panel prioritised the
importance of specific topics and questions, for which
evidence synthesis was performed based on SRs. In
addition, guideline recommendations were graded accord-
ing to the 2009 Oxford Centre for Evidence-based Medicine
Levels of Evidence. The aim of the panel is to strengthen the
methodological quality of evidence synthesis to further
improve the overall quality of the guideline and its
recommendations, which in turn will enhance its dissemi-
nation and uptake and its impact on patients, clinicians, and
health care organisations.
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